Biosensis/Sheep antibody to alpha synuclein (116-131): affinity purified/S-075-50/50 µg-蚂蚁淘商城

新闻动态

Biosensis/Sheep antibody to alpha synuclein (116-131): affinity purified/S-075-50/50 µg

2024-04-27

Description	Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinsons disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.
Batch No.	See product label
Unit size	50 µg
Antigen	A synthetic peptide (CMPVDPDNEAYEMPSEE) of human alpha synuclein protein (aa: 116-131) conjugated to diphtheria toxoid has been used as the immunogen.
Other Names	Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
Accession	SYUA_HUMAN
Produced in	Sheep
Purity	Affinity purified and dialysed against phosphate buffered saline (PBS). Contains 0.02% sodium azide.
Applications	IHC, WB, ELISA. Recommended to be used at a concentration of 1µg/ml for immunohistochemistry (Paraffin sections); 0.5 µg/ml for WB and immunoblot. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Specificity	This antiserum specifically detects alpha synuclein.
Cross-reactivity	This antibody is known to react with alpha synuclein of human, mouse, rat and other rodents.
Blast it	If you would like to use this product in another species other than those specified here, or to see the shared identity between the immunogen used here in different speices and/or other molecules, simply copy the immunogen (from the Immunogen field) and paste it HERE and blast/format it. Note that, antisera raised against synthetic peptides are quite often very specific for that peptide ie, only one single amino acid difference may be enough to restrict the specificity to a particular molecule. Regardless, you can always contact us if you need assistance with this.
Form	Lyophilised
Reconstitution	Reconstitute in 50 µl of sterile water. Centrifuge to remove any insoluble material.
Storage	After reconstitution keep aliquots at -20ºC for a higher stability, and at 4ºC with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
Expiry Date	12 months after purchase
Specific References	1. Kuo Y.M. et al. (2010) Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet. May 1;19(9):1633-502. Pelkonen A. et al. (2010) Stimulated dopamine overflow and alpha-synuclein expression in the nucleus accumbens core distinguish rats bred for differential ethanol preference. J Neurochem. 2010 Aug;114(4):1168-76.3. Alves et al. (2008) Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease Hum Mol Genet. 2008 Jul 15;17(14):2071-83.
References	1. Lundvig et al, Brain Res Mol Brain Res 134, 3-17 (Mar 24, 2005).2. Bennett, Pharmacol Ther 105, 311-31 (Mar, 2005).3. Vekrellis, et al., Mol Neurobiol 30, 1-21 (Aug, 2004).4. Martin, et al., Protein Pept Lett 11, 229-37 (Jun, 2004).5. Doherty, et al., Acta Neuropathol (Berl) 107, 169-75 (Feb, 2004).6. Goedert, Curr Opin Genet Dev 11, 343-51 (Jun, 2001).7. Saito, et al., J Neurol Sci 177, 48-59 (Aug 1, 2000).8. Lücking C.B. et al., Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908.9. Kahle, et al., Ann N Y Acad Sci 920, 33-41 (2000).10. Clayton, et al., Trends Neurosci 21, 249-54 (Jun, 1998).